中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 12
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(12): 2882-2886

Association between pancreatic cancer and diabetes

DOI: 10.3969/j.issn.1001-5256.2022.12.039
  • a.

    Department of Pancreatic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

  • b.

    Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

Research funding:

National Natural Science Foundation of China (82170651);

National Natural Science Foundation of China (81870442)

More Information
  • Corresponding author: WANG Weixing, sate.llite@163.com (ORCID: 0000-0002-3854-0083)
  • Received Date: 2020-07-30
  • Accepted Date: 2020-08-31
  • Published Date: 2022-12-20
    Abstract
  • Pancreatic cancer is a type of highly malignant digestive system tumor, with a 5-year overall survival rate of < 10%. In recent years, a large number of studies have shown that there is a two-way relationship between pancreatic cancer and diabetes; diabetes is not only one of the high-risk factors for pancreatic cancer, but also a paraneoplastic phenomenon caused by pancreatic cancer. Hyperglycemia and hyperinsulinemia in patients with type 2 diabetes are risk factors for pancreatic cancer, and on the contrary, pancreatic cancer cells cause the dysfunction of pancreatic β cells through autocrine or paracrine pathways and thus lead to the onset of pancreatic diabetes. This article reviews the epidemiology and pathogenesis of pancreatic cancer and the two-way relationship between pancreatic cancer and diabetes, so as to provide a reference for clinical practice.

     

    • FullText(HTML)
  • loading
    • References(51)
  • [1]
    SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
    [2]
    ROY A, SAHOO J, KAMALANATHAN S, et al. Diabetes and pancreatic cancer: Exploring the two-way traffic[J]. World J Gastroenterol, 2021, 27(30): 4939-4962. DOI: 10.3748/wjg.v27.i30.4939.
    [3]
    SHARMA A, SMYRK TC, LEVY MJ, et al. Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis[J]. Gastroenterology, 2018, 155(2): 490-500. DOI: 10.1053/j.gastro.2018.04.025.
    [4]
    SAH RP, NAGPAL SJ, MUKHOPADHYAY D, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(7): 423-433. DOI: 10.1038/nrgastro.2013.49.
    [5]
    KLEEFF J, COSTELLO E, JACKSON R, et al. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer[J]. Br J Cancer, 2016, 115(7): 887-894. DOI: 10.1038/bjc.2016.277.
    [6]
    BITTERMAN DS, WINTER KA, HONG TS, et al. Impact of diabetes and insulin use on prognosis in patients with resected pancreatic cancer: An ancillary analysis of NRG oncology RTOG 9704[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1): 201-211. DOI: 10.1016/j.ijrobp.2020.08.042.
    [7]
    KOO DH, HAN KD, PARK CY. The incremental risk of pancreatic cancer according to fasting glucose levels: Nationwide population-based cohort study[J]. J Clin Endocrinol Metab, 2019, 104(10): 4594-4599. DOI: 10.1210/jc.2019-00033.
    [8]
    LIAO WC, TU YK, WU MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis[J]. BMJ, 2015, 350: g7371. DOI: 10.1136/bmj.g7371.
    [9]
    SONG S, WANG B, ZHANG X, et al. Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: A meta-analysis[J]. PLoS One, 2015, 10(7): e0134321. DOI: 10.1371/journal.pone.0134321.
    [10]
    ANDERSEN DK, KORC M, PETERSEN GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer[J]. Diabetes, 2017, 66(5): 1103-1110. DOI: 10.2337/db16-1477.
    [11]
    RAGHAVAN SR, BALLEHANINNA UK, CHAMBERLAIN RS. The impact of perioperative blood glucose levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review[J]. Pancreas, 2013, 42(8): 1210-1217. DOI: 10.1097/MPA.0b013e3182a6db8e.
    [12]
    PANG Y, KARTSONAKI C, GUO Y, et al. Diabetes, plasma glucose and incidence of pancreatic cancer: A prospective study of 0.5 million Chinese adults and a meta-analysis of 22 cohort studies[J]. Int J Cancer, 2017, 140(8): 1781-1788. DOI: 10.1002/ijc.30599.
    [13]
    WOLPIN BM, BAO Y, QIAN ZR, et al. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer[J]. J Natl Cancer Inst, 2013, 105(14): 1027-1035. DOI: 10.1093/jnci/djt123.
    [14]
    TURATI F, ROSSI M, MATTIOLI V, et al. Diabetes risk reduction diet and the risk of pancreatic cancer[J]. Eur J Nutr, 2022, 61(1): 309-316. DOI: 10.1007/s00394-021-02646-5.
    [15]
    SHARMA A, KANDLAKUNTA H, NAGPAL S, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes[J]. Gastroenterology, 2018, 155(3): 730-739. DOI: 10.1053/j.gastro.2018.05.023.
    [16]
    MOLINA-MONTES E, COSCIA C, GÓMEZ-RUBIO P, et al. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses[J]. Gut, 2021, 70(2): 319-329. DOI: 10.1136/gutjnl-2019-319990.
    [17]
    PANNALA R, LEIRNESS JB, BAMLET WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus[J]. Gastroenterology, 2008, 134(4): 981-987. DOI: 10.1053/j.gastro.2008.01.039.
    [18]
    HART PA, BAICHOO E, BI Y, et al. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus[J]. Pancreatology, 2015, 15(2): 162-166. DOI: 10.1016/j.pan.2015.02.006.
    [19]
    BAO J, LIU D, SUN J, et al. Pancreatic cancer-associated diabetes mellitus is characterized by reduced β-cell secretory capacity, rather than insulin resistance[J]. Diabetes Res Clin Pract, 2022, 185: 109223. DOI: 10.1016/j.diabres.2022.109223.
    [20]
    ROHRMANN S, GROTE VA, BECKER S, et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition[J]. Br J Cancer, 2012, 106(5): 1004-1010. DOI: 10.1038/bjc.2012.19.
    [21]
    TRAJKOVIC- ARSIC M, KALIDERIS E, SIVEKE JT. The role of insulin and IGF system in pancreatic cancer[J]. J Mol Endocrinol, 2013, 50(3): R67-R74. DOI: 10.1530/JME-12-0259.
    [22]
    HOPKINS BD, PAULI C, DU X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors[J]. Nature, 2018, 560(7719): 499-503. DOI: 10.1038/s41586-018-0343-4.
    [23]
    HUA F, LI K, YU JJ, et al. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations[J]. Nat Commun, 2015, 6: 7951. DOI: 10.1038/ncomms8951.
    [24]
    ZHOU C, QIAN W, LI J, et al. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 302. DOI: 10.1186/s13046-019-1288-7.
    [25]
    RAHN S, ZIMMERMANN V, VIOL F, et al. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells[J]. Cancer Lett, 2018, 415: 129-150. DOI: 10.1016/j.canlet.2017.12.004.
    [26]
    LI W, ZHANG L, CHEN X, et al. Hyperglycemia promotes the epithelial-mesenchymal transition of pancreatic cancer via hydrogen peroxide[J]. Oxid Med Cell Longev, 2016, 2016: 5190314. DOI: 10.1155/2016/5190314.
    [27]
    KISS K, BAGHY K, SPISÁK S, et al. Chronic hyperglycemia induces trans-differentiation of human pancreatic stellate cells and enhances the malignant molecular communication with human pancreatic cancer cells[J]. PLoS One, 2015, 10(5): e0128059. DOI: 10.1371/journal.pone.0128059.
    [28]
    HAN L, MA Q, LI J, et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR[J]. PLoS One, 2011, 6(11): e27074. DOI: 10.1371/journal.pone.0027074.
    [29]
    DUAN Q, LI H, GAO C, et al. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 192. DOI: 10.1186/s13046-019-1209-9.
    [30]
    WU D, HU D, CHEN H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer[J]. Nature, 2018, 559(7715): 637-641. DOI: 10.1038/s41586-018-0350-5.
    [31]
    INCIO J, LIU H, SUBOJ P, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy[J]. Cancer Discov, 2016, 6(8): 852-869. DOI: 10.1158/2159-8290.CD-15-1177.
    [32]
    INCIO J, TAM J, RAHBARI NN, et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity[J]. Clin Cancer Res, 2016, 22(12): 2993-3004. DOI: 10.1158/1078-0432.CCR-15-1839.
    [33]
    WHATCOTT CJ, DIEP CH, JIANG P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer[J]. Clin Cancer Res, 2015, 21(15): 3561-3568. DOI: 10.1158/1078-0432.CCR-14-1051.
    [34]
    SCHMITZ J, DITTMAR IC, BROCKMANN JD, et al. Defense against reactive carbonyl species involves at least three subcellular compartments where individual components of the system respond to cellular sugar status[J]. Plant Cell, 2017, 29(12): 3234-3254. DOI: 10.1105/tpc.17.00258.
    [35]
    YAO D, BROWNLEE M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands[J]. Diabetes, 2010, 59(1): 249-255. DOI: 10.2337/db09-0801.
    [36]
    DINORCIA J, LEE MK, MOROZIEWICZ DN, et al. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer[J]. J Gastrointest Surg, 2012, 16(1): 104-112; discussion 112. DOI: 10.1007/s11605-011-1754-9.
    [37]
    SWAMI P, THIYAGARAJAN S, VIDGER A, et al. RAGE up-regulation differently affects cell proliferation and migration in pancreatic cancer cells[J]. Int J Mol Sci, 2020, 21(20): 7723. DOI: 10.3390/ijms21207723.
    [38]
    LECLERC E, VETTER SW. The role of S100 proteins and their receptor RAGE in pancreatic cancer[J]. Biochim Biophys Acta, 2015, 1852(12): 2706-2711. DOI: 10.1016/j.bbadis.2015.09.022.
    [39]
    MENINI S, IACOBINI C, DE LATOULIERE L, et al. The advanced glycation end-product NE-carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention[J]. J Pathol, 2018, 245(2): 197-208. DOI: 10.1002/path.5072.
    [40]
    KANG R, HOU W, ZHANG Q, et al. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer[J]. Cell Death Dis, 2014, 5: e1480. DOI: 10.1038/cddis.2014.445.
    [41]
    MENINI S, IACOBINI C, DE LATOULIERE L, et al. Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in KrasG12D/+ mice[J]. J Exp Clin Cancer Res, 2020, 39(1): 152. DOI: 10.1186/s13046-020-01665-0.
    [42]
    AGGARWAL G, RAMACHANDRAN V, JAVEED N, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice[J]. Gastroenterology, 2012, 143(6): 1510-1517. DOI: 10.1053/j.gastro.2012.08.044.
    [43]
    PANG W, YAO W, DAI X, et al. Pancreatic cancer-derived exosomal microRNA-19a induces β-cell dysfunction by targeting ADCY1 and EPAC2[J]. Int J Biol Sci, 2021, 17(13): 3622-3633. DOI: 10.7150/ijbs.56271.
    [44]
    TAVANO F, FONTANA A, MAZZA T, et al. Early-Onset diabetes as risk factor for pancreatic cancer: mirna expression profiling in plasma uncovers a role for mir-20b-5p, mir-29a, and mir-18a-5p in diabetes of recent diagnosis[J]. Front Oncol, 2020, 10: 1567. DOI: 10.3389/fonc.2020.01567.
    [45]
    SU J, PANG W, ZHANG A, et al. Exosomal miR-19a decreases insulin production by targeting Neurod1 in pancreatic cancer associated diabetes[J]. Mol Biol Rep, 2022, 49(3): 1711-1720. DOI: 10.1007/s11033-021-06980-z.
    [46]
    ŠKRHA J, BUŠEK P, UHROVÁ J, et al. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss[J]. Pancreatology, 2017, 17(1): 89-94. DOI: 10.1016/j.pan.2016.12.004.
    [47]
    ZHANG Y, HUANG S, LI P, et al. Pancreatic cancer-derived exosomes suppress the production of GIP and GLP-1 from STC-1 cells in vitro by down-regulating the PCSK1/3[J]. Cancer Lett, 2018, 431: 190-200. DOI: 10.1016/j.canlet.2018.05.027.
    [48]
    JAVEED N, SAGAR G, DUTTA SK, et al. Pancreatic cancer-derived exosomes cause paraneoplastic β-cell dysfunction[J]. Clin Cancer Res, 2015, 21(7): 1722-1733. DOI: 10.1158/1078-0432.CCR-14-2022.
    [49]
    WANG L, ZHANG B, ZHENG W, et al. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway[J]. Sci Rep, 2017, 7(1): 5384. DOI: 10.1038/s41598-017-05541-4.
    [50]
    American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S15-S33. DOI: 10.2337/dc21-S002.
    [51]
    CARRERAS-TORRES R, JOHANSSON M, GABORIEAU V, et al. The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a Mendelian randomization study[J]. J Natl Cancer Inst, 2017, 109(9): djx012. DOI: 10.1093/jnci/djx012.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2206) PDF downloads(84) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return